Gallegos-Arreola Martha Patricia, Zúñiga-González Guillermo Moisés, Gómez-Mariscal Karen, Rosales-Reynoso Mónica Alejandra, Luis Luis, Puebla-Pérez Ana María, Pineda-Razo Tomas
División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico.
Iran J Basic Med Sci. 2019 Mar;22(3):324-327. doi: 10.22038/ijbms.2019.26564.6507.
The rs712 polymorphism in a let-7 microRNA-binding site at gene has been associated with cancer. To examine its association with rs712 polymorphism, we analyzed Mexican individuals with colorectal cancer (CRC) and healthy subjects.
Genotyping of the rs712 polymorphism was performed by polymerase chain reaction in 281 controls and 336 CRC patients.
The observed frequencies of rs712 polymorphism indicated an associated protective factor for CRC (=0.032). An association between genotype and the disease was evident in: colon localization (allele odds ratio (OR) 3.82, 95% confidence Intervals (CI) 2.77-5.28, =0.0001), node metastasis (genotype OR 2.49, 95% CI 1.45-4.28, =0.0009), poor differentiation (genotype GT, OR 2.35, 95% CI 1.35-4.1, =0.0033), and poor chemotherapy response (genotype GT, OR 2.6, 95% CI 1.7-4.24, =0.0001).
Comparison of the data from patients with control group showed that polymorphism of rs712 in gene was protective factor, which was associated with susceptibility for CRC. However, the genotypes and of rs712 polymorphism in could contribute significantly to colon localization, node metastasis, poor differentiation and poor chemotherapy response in CRC patients in this sample population.
基因中let-7微小RNA结合位点的rs712多态性与癌症相关。为研究其与rs712多态性的关联，我们分析了墨西哥的结直肠癌（CRC）患者和健康受试者。
采用聚合酶链反应对281名对照者和336名CRC患者进行rs712多态性基因分型。
rs712多态性的观察频率表明其为CRC的相关保护因素（P = 0.032）。基因型与疾病之间的关联在以下方面明显：结肠定位（等位基因优势比（OR）3.82，95%置信区间（CI）2.77 - 5.28，P = 0.0001）、淋巴结转移（基因型OR 2.49，95% CI 1.45 - 4.28，P = 0.0009）、低分化（基因型GT，OR 2.35，95% CI 1.35 - 4.1，P = 0.0033）以及化疗反应差（基因型GT，OR 2.6，95% CI 1.7 - 4.24，P = 0.0001）。
患者与对照组数据比较表明，基因中rs712多态性是保护因素，与CRC易感性相关。然而，该样本人群中基因rs712多态性的基因型GG和GT可能对CRC患者的结肠定位、淋巴结转移、低分化及化疗反应差有显著影响。
